CVOT, cardiovascular outcome trial
Individual articles are based upon the opinions of the respective author, who retains copyright as marked
The TGA reports a number of adverse events and other concerns received for unapproved peptide products, which include: severe allergic reactions, requiring doses of adrenaline and hospitalisation systemic inflammatory response syndrome (SIRS) (severe inflammation in the body), requiring hospital management generalised hypersensitivity symptoms such as fullbody intense itching, palpitations, pain and sweating wide ranging body side effects, including insomnia, blurred vision, extreme tiredness, flulike illness, joint pain and skin sensitivity musculoskeletal injuries, including plantar fasciitis and Achilles tendinitis, and poor product quality, including unsealed packaging from an online supplier
RNA quality was verified by the use of amplification efficiency of the reference gene ( HPRT1 )
doi:10.1097/BOR.0b013e3283090463 15